Oral Treatment in Phase 2 Trial, NYX-458, Seen to Aid Cognition in Primate Model Study
Feb 05, 2020 07:00 am | Marisa Wexler
 Aptinyx‘s investigational oral compound NYX-458 was able to ease cognitive difficulties in a non-human primate model of Parkinson’s disease, including attention, working memory and executive thinking, a study reports. Its findings also suggest that NYX-458 — now in a Phase 2 clinical trial (NCT04148391) enrolling patients across the U.S. — does not interfere with levodopa treatment. […]
The post Oral Treatment in Phase 2 Trial, NYX-458, Seen to Aid Cognition in Primate Model Study appeared first on Parkinson's News Today. |
The other day, I filled out a form requesting my name and email address. It also asked me to check a little box. That was it. So I filled out my information and left the little box unchecked. It took me about 37 seconds to fill out the form and ignore that little box. Anyone […]
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Qynapse‘s QyScore, a software that aids in analyzing brain scans taken by magnetic resonance imaging (MRI). The software, which is compatible with routine imaging workflows, includes an advanced user interface and automatically-generated patient reports. Results are presented in comparison to data on people […]
VistaGen Therapeutics will begin a Phase 2 clinical trial to evaluate its lead candidate AV-101 as a potential treatment to reduce dyskinesia (abnormal involuntary movements) induced by levodopa in patients with Parkinson’s disease, after the U.S. Food and Drug Administration (FDA) cleared the company’s investigational new drug (IND) application. Parkinson’s is characterized by the loss […]
The first three winners of the Parkinson’s Foundation’s new Physical Therapy Faculty Award will use their up to $10,000 grant for projects aimed at putting exercise to work in improving patients’ lives. The program underscores an increasing need, as more patients live longer, for physical therapists trained in Parkinson’s. The disorder affects roughly seven to 10 million individuals globally, […]
